Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Recruiting × Neoadjuvant Therapy × Clear all

Phase

Phase 2 34 Phase 3 20 Phase NA 13 Phase EARLY_PHASE1 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Unknown 5 Completed 4 Not yet recruiting 3 Withdrawn 2 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 1

Interventions

Cisplatin 22 pembrolizumab 16 Gemcitabine 14 Drug Therapy 14 Carboplatin 14 Paclitaxel 13 Dexamethasone 12 Magnetic Resonance Spectroscopy 10 Bevacizumab 10 venetoclax 8 atezolizumab 8 Docetaxel 8 Specimen Handling 7 Pemetrexed 7 Oxaliplatin 7 Nivolumab 7 Cyclophosphamide 7 Radiotherapy 6 Methotrexate 6 Capecitabine 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 Standard of Care 5 Cytarabine 5 Androgen Antagonists 5 tislelizumab 4 spartalizumab 4 pertuzumab 4 blinatumomab 4 Vincristine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04973306 2022-06-30

iCROSS

Shanghai Zhongshan Hospital

Phase 2/3 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡